Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 2/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24590580 | 1.00 | JAK1 (0.33) | JAK1KDM4EDDB1CRBNALDH1A1 | |
| SCHEMBL30111817 | 0.87 | HCAR1 (0.41) | JAK1USP30GPR119HCAR1FPR2 | |
| SCHEMBL18289981 | 0.87 | HCAR1 (0.41) | JAK1USP30GPR119HCAR1FPR2 | |
| SCHEMBL18818280 | 0.87 | HCAR1 (0.41) | JAK1USP30GPR119HCAR1FPR2 | |
| SCHEMBL18285718 | 0.87 | HCAR1 (0.41) | JAK1USP30GPR119HCAR1FPR2 | |
| SCHEMBL18818279 | 0.87 | HCAR1 (0.41) | JAK1USP30GPR119HCAR1FPR2 | |
| SCHEMBL29737131 | 0.83 | KDM4E (0.37) | JAK1KDM4ESPRCCNT1CDK9 | |
| SCHEMBL24590579 | 0.83 | KDM4E (0.37) | JAK1KDM4ESPRCCNT1CDK9 | |
| SCHEMBL22902683 | 0.82 | JAK1 (0.38) | JAK1ALDH1A1JAK3 | |
| SCHEMBL22902497 | 0.81 | ALDH1A1 (0.34) | ALDH1A1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624030-B2 | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof | PRINCIPIA BIOPHARMA INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20240051955-A1 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | GENZYME CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4267572-A1 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3- DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | GENZYME CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140511-A1 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3- DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | GENZYME CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051955-A1 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | ADRA2C, P2RY4, HTR2C | JAK1 606/4885KDM4E 1632/4885DDB1 3368/4885 |
| US-12624030-B2 | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof | ADRA1D, ADRA2C, P2RY1 | JAK1 35/4885KDM4E 1651/4885DDB1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.